AscellaHealth’s Post

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Navigating the funding landscape can be tricky for biotech companies at all stages, from initial research and clinical trials to scaling up capabilities. Our recent roundtable discussions with over 90 Biotech CEOs, held in partnership with AusBiotech, shed light on the challenges and opportunities shaping the industry. Discover how to navigate the complexities of funding and innovation in the biotech sector in our latest article: https://okt.to/ugJm1o #Biotech #LifeSciences

Exciting insights from our recent roundtables, hosted in partnership with @AusBiotech. We were joined by more than 90 Biotech CEOs to discuss funding challenges, navigating regulatory changes, and talent acquisition. Read more about our discussions and how we can support your journey: https://lnkd.in/gwNc4P48

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #5. We are responsible: We take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality. We are self-motivated and rely on each other to operate and perform at the highest levels. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Is your biotech firm harnessing Competitive Insights (CI) to create value and secure strategic partnerships? Our latest white paper explores how CI can differentiate products, anticipate competitor moves and boost R&D decisions. Download here: https://bit.ly/3zSr1jW #Biotech #CompetitiveIntelligence #CompetitiveInsights

Join Guidehouse's Life Sciences Commercial Transformation leaders at the Fierce Biotech Summit in Boston on September 30. Connect with industry leaders and executives to learn about advancements, innovations, and the future of biotech. #productlaunch #biotech #innovation

The biotech industry continues to grow and scale up, and biomanufacturing has become an increasingly important aspect of the field. As so many components are involved in producing biopharmaceuticals, microbial, cell-based or mRNA products, knowing where to start and with whom to partner is crucial. There are many things to keep in mind: 👉 staying up-to-date on the latest industry trends and advancements, 👉 ensuring the quality of the products, 👉 understanding of the regulatory landscape surrounding biomanufacturing, etc. Our panel will delve into a range of crucial topics that biotech companies inevitably encounter in their operations. Join us during #CEBioForum2024 conference: "How to handle biomanufacturing?" ❇️ Dr Adriana Kiędzierska - Mencfeld - Polpharma Biologics ❇️ Lukasz Paciorkowski - A4BEE ❇️ Dominik Lipka PhD Eng. - SyVento BioTech ❇️ Monika Kozdron-Sikorska - ExecMind. Life Science Executive Search #CEBioForum2024 #biomanufacturing #bioproduction

High attendance at our panel discussion with representatives of the investor, industry and payer communities highlighting the importance of considering payers‘ perspectives as early as at preclinical stage #marketaccess #payers #biotech #syneoshealth #innovation #swissbiotechday

Excited to share McKinsey’s latest report on the European biotech financing landscape based on our presentation at Bio€quity Europe 2024 a few weeks back. My key takeaway from the report? The biotech industry started 2024 with some positive trends on financing and these trends are bringing a sentiment of cautious optimism to both biotech companies and investors. Check out the infographic below for other key takeaways and read the report for more strategic implications and insights for investors and biotech companies alike: https://lnkd.in/ey-YdTEa #Biotech #BiotechInvestments #FutureOfBiotech #BioEquity

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #6. We are focused: To ensure alignment with our mission, we take a focused approach to our delivery. We wisely utilise our resources and pay attention to our priorities. We balance pursuing our ambitious goals and innovations with our ability to ”focus and finish”. We focus on our most important work, and we are clear on our daily priorities to deliver our collective goals and mission. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery